Significant Improvement in Core Operating Income
Core operating income increased by JPY 79.2 billion year-over-year to JPY 108.7 billion, driven by strong sales at Sumitomo Pharma and favorable foreign exchange and tax adjustments.
Sumitomo Pharma Performance
Sumitomo Pharma's core operating income increased by JPY 94.3 billion year-over-year, attributed to expanded sales of ORGOVYX and GEMTESA, as well as gains from partial divestiture of the Asian business.
Essential & Green Materials Segment Improvement
Despite a loss, the Essential & Green Materials segment saw an improvement of JPY 16.1 billion year-over-year due to better profit margins from synthetic resins and aluminum.
Financial Position Strengthening
Interest-bearing liabilities decreased by JPY 94.5 billion, and equity increased by JPY 105.2 billion compared to the previous term's end.